Skip to content

Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls

Impact of Vitamin B12 Supplementation With Iron and Folic Acid on Adolescent Girls

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01490944
Enrollment
360
Registered
2011-12-13
Start date
2012-01-31
Completion date
2013-01-31
Last updated
2012-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaemia

Brief summary

The study is a clinical trial to assess the effectiveness of Vitamin B12 supplementation along with Iron Folic Acid (IFA) in combating anaemia. Adolescent anaemic girls will be randomly divided into two groups. * Group 1: IFA weekly supplementation along with Information, Education, Communication sessions * Group 2: IFA + Cyanocobalamin weekly supplementation along with Information, Education, Communication sessions Duration of supplementation: 6 months

Detailed description

The study is a randomized clinical trial to be conducted on mild or moderately anaemic adolescent girls (11-18 yrs) in a slum in Delhi. Anaemic adolescent girls (n=360) will be randomly divided into two groups. Group 1(n=180) will be given weekly supplementation of Iron (100 mg) and Folic acid (500 mcg) for six months, whereas group 2 (n=180) will be given weekly supplementation of Iron Folic Acid and cyanocobalamin (Vitamin B12) to assess the impact of Vitamin B12 supplementation on reducing the prevalence of anaemia. For first six weeks, 500 mcg/ week of cyanocobalamin will be given , followed by maintenance dose of 15 mcg/ week for rest of 20 weeks. Anthropometric measurements and dietary information will be collected besides biochemical analysis. IEC sessions will be organized for both the groups.The study hypothesis is that Vitamin B12 supplementation along with iron folic acid (IFA) is more effective in reducing the prevalence of anaemia as compared to IFA supplementation alone.

Interventions

DRUGIron, Folic acid and Cyanocobalamin

Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks

Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months

Sponsors

Delhi University
CollaboratorOTHER
Indian Council of Medical Research
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
11 Years to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Willingness to participate * Unmarried or married (who still reside with their parents, i.e. prior to 'Gauna') adolescent girl.

Exclusion criteria

* Severe anaemia * Pregnant Adolescent girls * Medical conditions like TB, Cancer etc

Design outcomes

Primary

MeasureTime frameDescription
Change in hemoglobin levelat baseline and after 6 monthsThe primary outcome would be to assess the change in hemoglobin level after intervention with Iron Folic acid & cyanocobalamin weekly supplementation for 6 months and to compare the results with the group 1 in which only Iron and Folic acid would be supplemented

Secondary

MeasureTime frameDescription
Change in serum ferritin, folic acid and vitamin B12 levelsat baseline and at end of 6 monthsThe secondary outcome would be to assess the change in level of serum ferritin, folic acid and Vitamin B12 after intervention with Iron Folic acid & cyanocobalamin weekly supplementation for 6 months and to compare the results with the group 1 in which only Iron and Folic acid would be supplemented

Countries

India

Contacts

Primary ContactDr. Gurdayal S Toteja, Ph.D
gstoteja@gmail.com+91-11-23731633
Backup ContactPriyanka Gupta, M.Sc
priyankaicmr@gmail.com+91-11-26890602

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026